Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MEK162 in Noonan Syndrome Hypertrophic Cardiomyopathy

Summary

The purpose of the study is to determine whether the ability of MEK162 to antagonize MEK activation in NS HCM patients, who usually have upstream mutations in the Ras-Raf-Mek-Erk pathway that lead to MEK activation, would be beneficial over a 6 month treatment period in hypertrophy regression.

Timeline

Start

2012-02

Primary completion

2017-05

Completion

—

Outcome

Outcome not reported

Stopped (Business): “Study was withdrawn due to scientific and business considerations.”

Drugs

Indications

No indication recorded.